(Press-News.org) A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.
The study by researchers at UCLA's Jonsson Comprehensive Cancer Center found that patients with the mutations in both the MEK1 and BRAF genes respond as well to the inhibitors as patients with the BRAF mutation alone. Another surprising finding is that the MEK1 and BRAF mutations exist together in these patients, despite the fact that they drive the same cell signaling pathway. That discovery also bucks conventional wisdom, said study senior author Dr. Roger Lo, an assistant professor of dermatology and molecular and medical pharmacology and a Jonsson Cancer Center scientist. "This study is a good example of why scientists should not always rely on what we expect to find," Lo said. "We expected that this second mutation was involved in drug resistance and it wasn't. We also expected that only one mutation would exist in this signaling pathway, and that also was wrong." The study appears April 1, 2012 in the early online edition of Cancer Discovery, a peer-reviewed journal of the American Association of Cancer Research. About 50 percent of patients with metastatic melanoma, or 4,000 people a year, have the BRAF mutation and can be treated with the inhibitor Zelboraf, two pills taken twice daily. Zelboraf was approved by the U.S. Food and Drug Administration for use in metastatic melanoma in August 2011. Many other common human cancers, including colon, thyroid and lung, also harbor BRAF-mutated subsets, Lo said.
Use of BRAF inhibitors led to a response in about 60 percent of those with the mutation, Lo said. After responding initially, most of those patients become resistant to the drug. Lo and his team of Jonsson Cancer Center scientists have been studying the mechanisms of resistance to see if they can either prevent it or find a way to re-sensitize the tumor to treatment. It was part of this work that led Lo to examine what role the MEK1 mutation might or might not be playing in that resistance.
"MEK1 is rarely mutated in cancers, but we found in this study that it was frequently associated with BRAF mutations," Lo said. "The presence of both mutated MEK1 and BRAF might have been considered a biomarker for patients who would not respond to BRAF inhibitors. We were quite surprised when we found that patients with both mutations respond to BRAF inhibitors as well as those with only the BRAF mutation."
To explore the association between the two mutations, Lo and his team analyzed tumor samples from 31 melanoma patients treated with a BRAF inhibitor. Among those patients, 16 percent of samples carried the double mutations in tumors before the cancer was treated, Lo said. The findings were confirmed use melanoma cells lines grown in Lo's laboratory.
Going forward, Lo and his team will look at approaches using inhibitors of MEK1 with BRAF inhibitors to determine if patients with the double mutations respond better and for longer periods. They will also try to understand why MEK1 mutations occur quite frequently among melanomas. About 15 percent of the patients with BRAF mutations also have a mutated MEK1, Lo said. "As BRAF inhibitors gain widespread use for advance melanoma treatment, biomarkers for drug sensitivity or resistance are urgently needed," the study states. "We identify here concurrent activating mutations in BRAF and MEK1 in melanomas and show that the presence of a downstream mutation in MEK1 does not necessarily make BRAF mutant melanomas resistant to BRAF inhibitors." About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.
###The study was funded by the Bud and Sue Selig Innovative Research Grant from Stand Up to Cancer, Burroughs Wellcome Fund, the Seaver Institute, the Richard C. Seaver Charitable Trust, National Cancer Institute, STOP CANCER, V Foundation for Cancer Research, Melanoma Research Foundation, Melanoma Research Alliance, American Skin Association, Caltech-UCLA Joint Center for Translational Medicine, Sidney Kimmel Foundation for Cancer Research, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Wendy and Ken Ruby and Louise Belley and Richard Schnarr.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2011, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 11 of the last 12 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
Second mutation in BRAF-mutated melanoma doesn't contribute to resistance
2012-04-02
ELSE PRESS RELEASES FROM THIS DATE:
Study finds protective gene in fat cells
2012-04-02
BOSTON -- In a finding that may challenge popular notions of body fat and health, researchers at Beth Israel Deaconess Medical Center (BIDMC) have shown how fat cells can protect the body against diabetes. The results may lead to a new therapeutic strategy for preventing and treating type 2 diabetes and obesity-related metabolic diseases, the authors say.
In the last decade, several research groups have shown that fat cells in people play a major role in controlling healthy blood sugar and insulin levels throughout the body. To do this crucial job, fat cells need a small ...
MDC-researchers elucidate molecular mechanism contributing to cardiomyopathy
2012-04-02
Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown. Professor Michael Gotthardt and Professor Norbert Hübner of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany, and colleagues have found that the RNA binding motif protein 20 (RBM20), a gene ...
Heart failure's effects in cells can be reversed with a rest
2012-04-02
Structural changes in heart muscle cells after heart failure can be reversed by allowing the heart to rest, according to research at Imperial College London. Findings from a study in rats published today in the European Journal of Heart Failure show that the condition's effects on heart muscle cells are not permanent, as has generally been thought. The discovery could open the door to new treatment strategies.
Heart failure means that the heart muscle is too weak or stiff to pump blood as effectively as it needs to, and it is commonly the result of a heart attack. Around ...
The role of physics in the sinking of the Titanic
2012-04-02
A century on from the sinking of the Titanic, science writer Richard Corfield takes a look at the cascade of events that led to the demise of the 'unsinkable' ship, taking into account the maths and physics that played a significant part.
At 11.40 p.m. on Sunday 14 April 1912 the Titanic, bound from Southampton to New York, struck an iceberg just off the coast of Newfoundland and became fully submerged within three hours, before dropping four kilometres to the bottom of the Atlantic.
There have been many stories recounting why the ship struck the iceberg and why two-thirds ...
Mechanism found connecting metastatic breast cancer and arthritis
2012-04-02
New research shows it may be no accident when doctors observe how patients suffering from both breast cancer and arthritis seem to have more aggressive cancer. However, the new-found interaction between the two diseases may also suggest a possible treatment.
A potential relationship between metastatic breast cancer and autoimmune arthritis, as suggested by past epidemiological studies, has led researchers from the University of North Carolina at Charlotte to perform a series of mouse model experiments that appear to confirm the connection.
"Epidemiological studies ...
Protein Aurora-A is found to be associated with survival in head and neck cancer
2012-04-02
CHICAGO, IL (April 1, 2012)––Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1.
The researchers found that patients whose tumors had higher levels of the protein known as Aurora-A had a shorter survival following surgery to remove their tumors than patients whose tumors had normal levels of the protein.
"This ...
The protein survivin could be a useful biomarker for pancreatic cancer
2012-04-02
CHICAGO, IL (April 1, 2012)––Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute. New research from scientists at Fox Chase Cancer Center in Philadelphia, which will be presented at the AACR Annual ...
Fox Chase scientists identify key protein players in hard-to-treat breast cancers
2012-04-02
CHICAGO, IL (April 1, 2012)––At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, however, the disease often becomes resistant to estrogen deprivation from the drugs—making treatment options more limited.
New findings that will be ...
New comparison of ocean temperatures reveals rise over the last century
2012-04-02
A new study contrasting ocean temperature readings of the 1870s with temperatures of the modern seas reveals an upward trend of global ocean warming spanning at least 100 years.
The research led by Scripps Institution of Oceanography at UC San Diego physical oceanographer Dean Roemmich shows a .33-degree Celsius (.59-degree Fahrenheit) average increase in the upper portions of the ocean to 700 meters (2,300 feet) depth. The increase was largest at the ocean surface, .59-degree Celsius (1.1-degree Fahrenheit), decreasing to .12-degree Celsius (.22-degree Fahrenheit) at ...
Raising the school leaving – while learning from another age
2012-04-02
In April 1947 the post-war Labour Government raised the school leaving age from 14 to 15 and paved the way for a further increase to 16 in 1972. Now, 65 years later, as the UK prepares to raise the 'education participation age' to 17 in 2013 and to 18 in 2015, new research reveals that the transitions of 1947 and 1972 met with more controversy and difficulty than previously thought.
In a study funded by the Economic and Social Research Council, Dr Tom Woodin and Professor Gary McCulloch of the Institute of Education, London, analysed the debate surrounding the implementation ...